BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35778350)

  • 21. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment.
    Lim KS; Mimura K; Kua LF; Shiraishi K; Kono K
    J Immunother; 2018; 41(6):261-273. PubMed ID: 29683892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.
    Bhattacharya S; Muhammad N; Steele R; Kornbluth J; Ray RB
    Cancer Prev Res (Phila); 2017 Jun; 10(6):337-344. PubMed ID: 28465362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
    Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
    Front Immunol; 2021; 12():737311. PubMed ID: 34557197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.
    Bernareggi D; Xie Q; Prager BC; Yun J; Cruz LS; Pham TV; Kim W; Lee X; Coffey M; Zalfa C; Azmoon P; Zhu H; Tamayo P; Rich JN; Kaufman DS
    Nat Commun; 2022 Apr; 13(1):1899. PubMed ID: 35393416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
    Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
    Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
    Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
    Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
    Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
    J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
    Yu Y; Lee NY
    Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-18 synergism with interleukin-2 in cytotoxicity and NKG2D expression of human natural killer cells.
    Qi YY; Lu C; Ju Y; Wang ZE; Li YT; Shen YJ; Lu ZM
    Asian Pac J Cancer Prev; 2014; 15(18):7857-61. PubMed ID: 25292077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
    Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
    Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
    Bisheshar SK; De Ruiter EJ; Devriese LA; Willems SM
    Oncoimmunology; 2020; 9(1):1747345. PubMed ID: 32363116
    [No Abstract]   [Full Text] [Related]  

  • 36. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
    Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
    J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
    Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
    Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased sMICA and TGFβ
    Klöß S; Chambron N; Gardlowski T; Arseniev L; Koch J; Esser R; Glienke W; Seitz O; Köhl U
    Oncoimmunology; 2015 Nov; 4(11):e1055993. PubMed ID: 26451327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.